Drug Profile
BCI 838
Alternative Names: BCI-838Latest Information Update: 14 Sep 2022
Price :
$50
*
At a glance
- Originator Taisho Pharmaceutical
- Developer BrainCells
- Class Antidementias; Antidepressants
- Mechanism of Action Metabotropic glutamate receptor 2 antagonists; Metabotropic glutamate receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease
- No development reported Major depressive disorder
Most Recent Events
- 31 Jul 2022 Preclinical trials in Alzheimer's disease in USA (PO) Before July 2022
- 31 Jul 2022 Pharmacodynamics and adverse events data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2022 (AAIC-2022)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Netherlands (PO)